Lung cancer is the most common malignant tumor with the highest mortality, and about 84%
are non-small cell lung cancer (NSCLC). However, only a small proportion of patients with …

Lung cancer is worldwide the most common malignancy. Standard of care treatments for
early-stage non-small-cell lung cancer (NSCLC) include surgery and adjuvant …

Simple Summary Immunotherapy with immune checkpoint inhibitors has recently brought a
paradigm shift in the treatment of non-small cell lung cancer (NSCLC), but until now, most …

Standard curative treatment of early-stage non-small cell lung cancer (NSCLC) involves
surgery in combination with postoperative (adjuvant) platinum-based chemotherapy where …

Opinion statement While cisplatin-based adjuvant chemotherapy has been the standard of
care for the past two decades, the recent introduction of immunotherapy has heralded an …

Lung cancer is the leading cause of cancer deaths in the world. Surgery is the most
potentially curative therapeutic option for patients with early-stage non-small cell lung …

Lung cancer mortality has decreased over the past decade and can be partly attributed to
advances in targeted therapy and immunotherapy. Immune checkpoint inhibitors (ICIs) have …

Background With a 5% improvement in 5-year overall survival achieved with current
neoadjuvant or adjuvant chemotherapy, new treatments for resectable non-small cell lung …

Currently, chemotherapy is the standard adjuvant treatment for early-stage non-small cell
lung cancer (NSCLC). However, adjuvant cisplatin-based chemotherapy after surgery has …

Surgery or concurrent chemoradiation are standard of care treatments for patients with
localized and locally advanced non-small cell lung cancer (NSCLC). While resection and …